Eli Lilly & Co. has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm ImClone Systems Inc. in a deal that tops earlier offers from competitor Bristol-Myers Squibb Co. Indianapols-based Lilly…

See more here:
Eli Lilly to buy ImClone for more than $6B